PLUS

HEADLINES TREATMENT REGIMENS FROM THE ADVISORY BOARD PUBLISHERS ALLIANCE TOOLS MULTIMEDIA CME

Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer Refractory to BCG

Share this article:
Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer Refractory to BCG
Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer Refractory to BCG


References

1. Weizer A.Z., Wasco M.J., Wang R., et al. Multiple adverse histological features increase the odds of under staging T1 bladder cancer. J Urol. 2009;182(3):59–65; discussion 65.

2. Andius P., Johansson S.L., Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology. 2007;70(4):758–762.

3. Cho KS, Seo HK, Joung JY, et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol. 2009;182(6):2625–2630.

4. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314–2330.

5. Raj G.V., Herr H, Serio A.M., et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol. 2007;177(4):1283–1286; discussion 1286.

6. Kulkarni G.S., Finelli A., Fleshner N.E., et al. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med. 2007;4(9):e284.

7. Malmström P.U., Sylvester R.J., Crawford D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256.

8. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–1129.

9. Van der Meijden A.P., Sylvester R, Oosterlinck W, et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol. 2005;48(3):363–371.

10. Gallagher B.L., Joudi F.N., Maymí J.L., et al. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology. 2008;71(2):297–301.

11. Morales A., Phadke K., Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol. 2009;181(3):1040–1045.

12. Steinberg G., Bahnson R., Brosman S., et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761–767.

13. Dalbagni G., Russo P., Bochner B., et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24(18):2729–2734.

14. Sockett L.J., Borwell J., Symes A., Parker T., Montgomery B.S.I., Barber N.J. (2008). Electro-motive drug administration (EMDA) of intravesical mitomycin-C in patients with high-risk non-invasive bladder cancer and failure of BCG immunotherapy. BJU Int. 101(suppl 5):50 abs #U17.

15. Witjes J.A., Hendricksen K., Gofrit O., Risi O., Nativ O. (2009). Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World Journal of Urology. 27(3):319–324.

Page 4 of 4
Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.
close

Next Article in From The Advisory Board

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in From The Advisory Board

What to Consider When It Comes to Surgery in Elderly Patients With Cancer

What to Consider When It Comes to Surgery ...

Dr. Jeffrey Farma provides his insight on treating the elderly patient population in the surgical oncology setting.

Improving Survival in Advanced NSCLC: Multiple Lines of Chemotherapy Make a Difference

Improving Survival in Advanced NSCLC: Multiple Lines of ...

Oncologists who care for non-small cell lung cancer (NSCLC) patients need to develop management strategies.

The Resurgence of Interest in Immune Therapy for Metastatic Renal Carcinoma

The Resurgence of Interest in Immune Therapy for ...

Immune therapies hold substantial promise to improve therapeutic options for patients with metastatic renal cancer.